Measuring Adherence to Antiretroviral Medications in Clinical Trials
ResearchPosted on rand.org 2000Published in: HIV Clinical Trials, v. 1, no. 1, July-Aug. 2000, p. 36-46
ResearchPosted on rand.org 2000Published in: HIV Clinical Trials, v. 1, no. 1, July-Aug. 2000, p. 36-46
Antiretroviral medications have the potential to transform HIV infection from a fatal to a chronic disease. One of the significant barriers to clinical success is medication nonadherence. Measuring adherence in clinical trials is increasingly important because inadequate adherence may explain some of the variation in clinical response in antiretroviral clinical trials. Additionally, to quantitate the success of interventions that improve adherence, accurate measures need to be utilized. This article summarizes commonly used adherence measures in HIV clinical trials and observational studies such as patient self-report, pill counts, plasma levels, and electronic monitoring. The merits and shortcomings of each measure are discussed.
This publication is part of the RAND external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.
RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.